摘要
目的探讨葛根素在脑缺血再灌注损伤(IRI)时对脑组织局部肾素-血管紧张素系统(RAS)的影响。方法选择Wistar大鼠60只,并按随机数字表法将其分为对照组(假手术)、模型组(线栓法成功制造大鼠脑IRI)和治疗组(线栓法成功制造大鼠脑IRI的同时给予葛根素进行干预);术后24 h处死实验动物,并采用Zea-Longa神经行为学评分评价大鼠的神经功能,HE染色观察大鼠脑组织的变性细胞指数(DCI),放射免疫法、Real-time PCR、Western blot检测大鼠脑组织RAS主要组分[血管紧张素Ⅱ(AngⅡ)、血管紧张素转化酶(ACE)、血管紧张素Ⅱ1型和2型受体(AT1R和AT2R)]的表达。结果模型组和治疗组大鼠的神经行为学评分、DCI、AngⅡ、ACE、AT1R和AT2R均明显高于对照组(P<0.05),当给予葛根素干预后,治疗组大鼠的神经行为学评分和DCI均较模型组下降(P<0.05),同时伴随着脑组织局部RAS主要组分的下降(P<0.05)。结论葛根素对大鼠脑IRI的保护作用可能与其抑制了脑组织局部RAS有关。
Objective To explore the effect of puerarin on the local cerebrum renin-angiotensin system(RAS) in cerebral ischemia reperfusion injury(IRI). Methods A total of 60 Wistar rats were selected and divided into the control group(sham operation), the model group(rats in the model group were established as cerebral IRI model by inserting a monofilament into middle cerebral artery) and the treatment group(rats in the treatment group were administered with puerarin after the cerebral IRI model was established) by random number table method. All rats were sacrificed 24 h after operation. The neurological function of rats was evaluated by Zea-Longa method. The denatured cell index(DCI) in cerebrum was observed by HE staining. Main components of renin-angiotensin system including angiotensinⅡ(AngⅡ), angiotensin converting enzyme(ACE), angiotensin type 1 receptors(AT1 R) and angiotensin type 2 receptors(AT2 R) were determined using radioimmunoassay, Real-time PCR and Western blot. Results The neurological function scores, DCI,AngⅡ, ACE, AT1 R and AT2 R in the model group and the treatment group rats increased significantly compared with those in the control group(P〈0.05). The neurological function scores and DCI after puerarin treatment were decreased significantly compared with those in the model group(P〈0.05), in the meantime, the main components of renin-angiotensin system were also inhibited by puerarin(P〈0.05).Conclusion The protective effect of puerarin on cerebral IRI in rats may have certain relationship to the inhibitory of the local RAS in cerebrum.
出处
《中国医药导报》
CAS
2018年第2期9-12,35,共5页
China Medical Herald
基金
国家自然科学基金资助项目(81601875
81772329)
山东省自然科学基金资助项目(ZR2016HB33)